Oestrogen receptor β ligand: A novel treatment to enhance endogenous functional remyelination

Brain

Volumn 133, Issue 10, 2010, Pages 2999-3016

  Crawford, Daniel K ^a   Mangiardi, Mario ^a   Song, Bingbing ^a   Patel, Rhusheet ^a   Du, Sienmi ^a   Sofroniew, Michael V ^a   Voskuhl, Rhonda R ^a   Tiwari Woodruff, Seema K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EAE; myelin sheath; neurodegeneration; neuroprotection; oligodendrocytes; remyelination

Indexed keywords

DIARYLPROPIONITRILE; ESTROGEN RECEPTOR BETA;

ACTION POTENTIAL; ALLERGIC ENCEPHALOMYELITIS; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; CORPUS CALLOSUM; DISEASE SEVERITY; ELECTRON MICROSCOPY; ELECTROPHYSIOLOGY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MOUSE; MYELIN SHEATH; NERVE CONDUCTION; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RANVIER NODE; REMYELINIZATION; AGONISTS; ANALYSIS OF VARIANCE; ANIMAL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; NERVE FIBER; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; AXONS; CORPUS CALLOSUM; ELECTROPHYSIOLOGY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ESTROGEN RECEPTOR BETA; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; MYELIN SHEATH; NERVE DEGENERATION; OLIGODENDROGLIA; SEVERITY OF ILLNESS INDEX;

EID: 77957681466     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq237     Document Type: Article

References (87)

1. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-504.
2. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, et al. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 2009; 57: 807-14.
3. Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligo-dendrocyte progenitor maturation. Nat Med 2005; 11: 966-72.
4. Bannerman PG, Hahn A, Ramirez S, Morley M, Bonnemann C, Yu S, et al. Motor neuron pathology in experimental autoimmune enceph-alomyelitis: studies in THY1-YFP transgenic mice. Brain 2005; 128: 1877-86.
5. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
6. Black JA, Newcombe J, Trapp BD, Waxman SG. Sodium channel expression within chronic multiple sclerosis plaques. J Neuropathol Exp Neurol 2007; 66: 828-37.
7. Bonzano L, Tacchino A, Roccatagliata L, Abbruzzese G, Mancardi GL, Bove M. Callosal contributions to simultaneous bimanual finger movements. J Neurosci 2008; 28: 3227-33.
8. Boroojerdi B, Hungs M, Mull M, Topper R, Noth J. Interhemispheric inhibition in patients with multiple sclerosis. Electroencephalogr Clin Neurophysiol 1998; 109: 230-7.
9. Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of oestrogen action. Ann N Y Acad Sci 2005; 1052: 57-74.
10. Brown DA, Sawchenko PE. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol 2007; 502: 236-60.
11. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 2002; 8: 613-19.
12. Calza L, Fernandez M, Giuliani A, Aloe L, Giardino L. Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 2002; 99: 3258-63.
13. Carswell HV, Macrae IM, Gallagher L, Harrop E, Horsburgh KJ. Neuroprotection by a selective oestrogen receptor beta agonist in a mouse model of global ischemia. Am J Physiol Heart Circ Physiol 2004; 287: H1501-4.
14. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346: 165-73.
15. Chaovipoch P, Jelks KA, Gerhold LM, West EJ, Chongthammakun S, Floyd CL. 17beta-estradiol is protective in spinal cord injury in post-and pre-menopausal rats. J Neurotrauma 2006; 23: 830-52.
16. Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 2004; 127: 294-303.
17. Crawford DK, Mangiardi M, Tiwari-Woodruff SK. Assaying the functional effects of demyelination and remyelination: revisiting field potential recordings. J Neurosci Methods 2009a; 182: 25-33.
18. Crawford DK, Mangiardi M, Xia X, Lopez-Valdes HE, Tiwari-Woodruff SK. Functional recovery of callosal axons following demyelination: a critical window. Neuroscience 2009b; 164: 1407-21.
19. Du S, Sandoval F, Trinh P, Voskuhl RR. Additive effects of combination treatment with anti-inflammatory and neuroprotective agents in experimental autoimmune encephalomyelitis. J Neuroimmunol 219: 64-74.
20. Dubal DB, Rau SW, Shughrue PJ, Zhu H, Yu J, Cashion AB, et al. Differential modulation of oestrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. Endocrinology 2006; 147: 3076-84.
21. Emery B, Cate HS, Marriott M, Merson T, Binder MD, Snell C, et al. Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. Proc Natl Acad Sci USA 2006; 103: 7859-64.
22. Fernandez M, Giuliani A, Pirondi S, D'Intino G, Giardino L, Aloe L, et al. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci USA 2004; 101: 16363-8.
23. Filippi M, Rocca MA, Falini A, Caputo D, Ghezzi A, Colombo B, et al. Correlations between structural CNS damage and functional MRI changes in primary progressive MS. Neuroimage 2002; 15: 537-46.
24. Franco PG, Silvestroff L, Soto EF, Pasquini JM. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol 2008; 21: 458-67.
25. Franklin K, Paxinos G. The mouse brain: in stereotaxic coordinates. San Diego: Academic Press; 2001.
26. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-55.
27. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-89.
28. Fuss B, Afshari FS, Colello RJ, Macklin WB. Normal CNS myelination in transgenic mice overexpressing MHC class I H-2L(d) in oligodendro-cytes. Mol Cell Neurosci 2001; 18: 221-34.
29. Garay L, Deniselle MC, Lima A, Roig P, De Nicola AF. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid Biochem Mol Biol 2007; 107: 228-37.
30. Gasperini C, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci 2009; 30 (Suppl 2): S179-83.
31. Gerstner B, Sifringer M, Dzietko M, Schuller A, Lee J, Simons S, et al. Estradiol attenuates hyperoxia-induced cell death in the developing white matter. Ann Neurol 2007; 61: 562-73.
32. Gold SM, Sasidhar MV, Morales LB, Du S, Sicotte NL, Tiwari-Woodruff SK, et al. Oestrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through oestrogen receptor alpha (ERalpha). Lab Invest 2009; 89: 1076-83.
33. Groeneveld GJ, van Muiswinkel FL, Sturkenboom JM, Wokke JH, Bar PR, van den Berg LH. Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS. Brain Res 2004; 1021: 128-31.
34. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, et al. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 2008; 28: 14189-201.
35. Hobom M, Storch MK, Weissert R, Maier K, Radhakrishnan A, Kramer B, et al. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol 2004; 14: 148-57.
36. Jones MV, Nguyen TT, Deboy CA, Griffin JW, Whartenby KA, Kerr DA, et al. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol 2008; 199: 83-93.
37. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology 1999; 52: 1230-8.
38. Kipp M, Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front Neuroendocrinol 2009; 30: 188-200.
39. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-76.
40. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Bruck W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008; 131: 1749-58.
41. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. Remyelination in multiple sclerosis. Mult Scler 1997; 3: 133-6.
42. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-18.
43. Linington C, Engelhardt B, Kapocs G, Lassman H. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 1992; 40: 219-24.
44. Liu Z, Li Y, Zhang J, Elias S, Chopp M. Evaluation of corticospinal axon loss by fluorescent dye tracing in mice with experimental autoimmune encephalomyelitis. J Neurosci Methods 2008; 167: 191-7.
45. MacKenzie-Graham A, Tiwari-Woodruff SK, Sharma G, Aguilar C, Vo KT, Strickland LV, et al. Purkinje cell loss in experimental autoimmune encephalomyelitis. Neuroimage 2009; 48: 637-51.
46. Mallon BS, Shick HE, Kidd GJ, Macklin WB. Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J Neurosci 2002; 22: 876-85.
47. Manson SC, Palace J, Frank JA, Matthews PM. Loss of interhemispheric inhibition in patients with multiple sclerosis is related to corpus callosum atrophy. Exp Brain Res 2006; 174: 728-33.
48. Manson SC, Wegner C, Filippi M, Barkhof F, Beckmann C, Ciccarelli O, et al. Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of inter-hemispheric neuronal inhibition. Exp Brain Res 2008; 187: 25-31.
49. Marin-Husstege M, Muggironi M, Raban D, Skoff RP, Casaccia-Bonnefil P. Oligodendrocyte progenitor proliferation and maturation is differentially regulated by male and female sex steroid hormones. Dev Neurosci 2004; 26: 245-54.
50. McMorris FA, Smith TM, DeSalvo S, Furlanetto RW. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 1986; 83: 822-6.
51. Meltser I, Tahera Y, Simpson E, Hultcrantz M, Charitidi K, Gustafsson JA, et al. Oestrogen receptor beta protects against acoustic trauma in mice. J Clin Invest 2008; 118: 1563-70.
52. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000; 123 (Pt 11): 2256-63.
53. Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treatment with an oestrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 2006; 26: 6823-33.
54. Narayanan SP, Flores AI, Wang F, Macklin WB. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 2009; 29: 6860-70.
55. Ozturk A, Smith SA, Gordon-Lipkin EM, Harrison DM, Shiee N, Pham DL, et al. MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler 16: 166-77.
56. Pagani E, Rocca MA, Gallo A, Rovaris M, Martinelli V, Comi G, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005; 26: 341-6.
57. Pang Y, Zheng B, Fan LW, Rhodes PG, Cai Z. IGF-1 protects oligodendrocyte progenitors against TNFalpha-induced damage by activation of PI3K/Akt and interruption of the mitochondrial apoptotic pathway. Glia 2007; 55: 1099-107.
58. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165-72.
59. Pelletier J, Suchet L, Witjas T, Habib M, Guttmann CR, Salamon G, et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001; 58: 105-11.
60. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5: 22-31.
61. Quesada A, Lee BY, Micevych PE. PI3 kinase/Akt activation mediates oestrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol 2008; 68: 632-44.
62. Rasmussen S, Wang Y, Kivisakk P, Bronson RT, Meyer M, Imitola J, et al. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalo-myelitis. Brain 2007; 130: 2816-29.
63. Reeves TM, Phillips LL, Povlishock JT. Myelinated and unmyelinated axons of the corpus callosum differ in vulnerability and functional recovery following traumatic brain injury. Exp Neurol 2005; 196: 126-37.
64. Reynolds R, Cenci di Bello I, Dawson M, Levine J. The response of adult oligodendrocyte progenitors to demyelination in EAE. Prog Brain Res 2001; 132: 165-74.
65. Romanelli RJ, Mahajan KR, Fulmer CG, Wood TL. Insulin-like growth factor-I-stimulated Akt phosphorylation and oligodendrocyte progenitor cell survival require cholesterol-enriched membranes. J Neurosci Res 2009; 87: 3369-77.
66. Rossouw JE, Harlan WR. Postmenopausal oestrogen and the risk of breast cancer. The need for randomized trials. Ann Epidemiol 1994; 4: 255-6.
67. Singer W. Development and plasticity of cortical processing architectures. Science 1995; 270: 758-64.
68. Slaets H, Hendriks JJ, van den Haute C, Coun F, Baekelandt V, Stinissen P, et al. CNs-targeted lif expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis. Mol Ther 2010; 18: 684-91.
69. Sribnick EA, Wingrave JM, Matzelle DD, Wilford GG, Ray SK, Banik NL. Oestrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res 2005; 82: 283-93.
70. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006; 60: 12-21.
71. Takao T, Flint N, Lee L, Ying X, Merrill J, Chandross KJ. 17beta-estradiol protects oligodendrocytes from cytotoxicity induced cell death. J Neurochem 2004; 89: 660-73.
72. Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. Differential neuro-protective and antiinflammatory effects of oestrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci\USA 2007; 104: 14813-18.
73. Tiwari-Woodruff S, Voskuhl RR. Neuroprotective and anti-inflammatory effects of oestrogen receptor ligand treatment in mice. J Neurol Sci 2009; 286: 81-5.
74. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-69.
75. Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, Granieri E, et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. Mult Scler 2006; 12: 578-85.
76. Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW, et al. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 2009; 29: 6367-78.
77. Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, et al. Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade. Pharmacol Ther 2010; 126: 82-93.
78. Wang M, Wang Y, Weil B, Abarbanell A, Herrmann J, Tan J, et al. Oestrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol 2009; 296: R972-8.
79. Warlop NP, Fieremans E, Achten E, Debruyne J, Vingerhoets G. Callosal function in MS patients with mild and severe callosal damage as reflected by diffusion tensor imaging. Brain Res 2008; 1226: 218-25.
80. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 2006; 7: 932-41.
81. Wensky AK, Furtado GC, Marcondes MC, Chen S, Manfra D, Lira SA, et al. IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J Immunol 2005; 174: 1416-23.
82. Wilson ME, Dimayuga FO, Reed JL, Curry TE, Anderson CF, Nath A, et al. Immune modulation by oestrogens: role in CNS HIV-1 infection. Endocrine 2006; 29: 289-97.
83. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, et al. Oestrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2006; 26: 535-41.
84. Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, et al. Brain oestrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA 2005; 102: 19198-203.
85. Zhang Z, Cerghet M, Mullins C, Williamson M, Bessert D, Skoff R. Comparison of in vivo and in vitro subcellular localization of oestrogen receptors alpha and beta in oligodendrocytes. J Neurochem 2004; 89: 674-84.
86. Zhu TS, Glaser M. Neuroprotection and enhancement of remyelination by estradiol and dexamethasone in cocultures of rat DRG neurons and Schwann cells. Brain Res 2008; 1206: 20-32.
87. Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune en-cephalomyelitis, EAE. Lab Invest 2010; 90: 774-86.